Afatinib 50 mg + letrozole 2.5 mg | Afatinib 40 mg + letrozole 2.5 mg | Afatinib 30 mg + letrozole 2.5 mg | All afatinib doses | |
---|---|---|---|---|
Number of patients, n (%) | 7 (100.0) | 13 (100.0) | 8 (100.0) | 28 (100.0) |
Progression-free rate (Protocol-defined criteria)a, n (%) [95 % CI] | 2 (28.57) [3.67–70.96] | 0 (0.00) [0.00–24.71] | 2 (25.00) [3.19–65.09] | 4 (14.29) [4.03–32.67] |
Progression-free rate (RECIST criteria), n (%) [95 % CI] | 2 (28.57) [3.67–70.96] | 1 (7.69) [0.19–36.03] | 2 (25.00) [3.19–65.09] | 5 (17.86) [6.06–36.89] |